Literature DB >> 23392810

[Radiological diagnosis of primary hepatic malignancy].

Benjamin Henninger1, Johannes Petersen, Werner Jaschke.   

Abstract

Modern radiology offers countless opportunities both in the detection but also in the characterization of primary liver malignancies. Ultrasound remains usually the first exploratory overview study whereat using ultrasound contrast agent for a further characterization of liver lesions improves this technique considerably. Advanced cross-sectional imaging methods can, in most cases, already provide an exact diagnosis. Thus, the CT is already considered a standard technique for liver imaging and magnetic resonance imaging has gained in recent years due to liver-specific contrast agents and faster sequences a central role in liver imaging. The following article provides an overview of these various radiological procedures and describes the different primary liver malignancies and their imaging characteristics.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23392810     DOI: 10.1007/s10354-013-0179-3

Source DB:  PubMed          Journal:  Wien Med Wochenschr        ISSN: 0043-5341


  76 in total

Review 1.  MR imaging of the liver using gadolinium chelates.

Authors:  R N Low
Journal:  Magn Reson Imaging Clin N Am       Date:  2001-11       Impact factor: 2.266

2.  Characterization of focal liver lesions with contrast-specific US modes and a sulfur hexafluoride-filled microbubble contrast agent: diagnostic performance and confidence.

Authors:  Emilio Quaia; Fabrizio Calliada; Michele Bertolotto; Sandro Rossi; Lorena Garioni; Laura Rosa; Roberto Pozzi-Mucelli
Journal:  Radiology       Date:  2004-08       Impact factor: 11.105

Review 3.  [Current diagnostics and therapy for carcinomas of the biliary tree and gallbladder].

Authors:  M Wiedmann; K Schoppmeyer; H Witzigmann; J Hauss; J Mössner; K Caca
Journal:  Z Gastroenterol       Date:  2005-03       Impact factor: 2.000

Review 4.  Fibrolamellar carcinoma of the liver: radiologic-pathologic correlation.

Authors:  J K McLarney; P T Rucker; G N Bender; Z D Goodman; N Kashitani; P R Ros
Journal:  Radiographics       Date:  1999 Mar-Apr       Impact factor: 5.333

5.  Real-time imaging with the sonographic contrast agent SonoVue: differentiation between benign and malignant hepatic lesions.

Authors:  Alexandra von Herbay; Christoph Vogt; Reinhard Willers; Dieter Häussinger
Journal:  J Ultrasound Med       Date:  2004-12       Impact factor: 2.153

6.  Dynamic breath-hold multiplanar spoiled gradient-recalled MR imaging with gadolinium enhancement for differentiating hepatic hemangiomas from malignancies at 1.5 T.

Authors:  W S Whitney; R J Herfkens; R B Jeffrey; C H McDonnell; K C Li; W J Van Dalsem; R N Low; I R Francis; J F Dabatin; G M Glazer
Journal:  Radiology       Date:  1993-12       Impact factor: 11.105

7.  Diagnosis of hepatic nodules 20 mm or smaller in cirrhosis: Prospective validation of the noninvasive diagnostic criteria for hepatocellular carcinoma.

Authors:  Alejandro Forner; Ramón Vilana; Carmen Ayuso; Lluís Bianchi; Manel Solé; Juan Ramón Ayuso; Loreto Boix; Margarita Sala; María Varela; Josep M Llovet; Concepció Brú; Jordi Bruix
Journal:  Hepatology       Date:  2008-01       Impact factor: 17.425

8.  Diagnosis and staging of pancreatic cancer: comparison of mangafodipir trisodium-enhanced MR imaging and contrast-enhanced helical hydro-CT.

Authors:  Wolfgang Schima; Reinhold Függer; Ewald Schober; Claudia Oettl; Peter Wamser; Florian Grabenwöger; J Mark Ryan; Gottfried Novacek
Journal:  AJR Am J Roentgenol       Date:  2002-09       Impact factor: 3.959

9.  Added value of breathhold diffusion-weighted MRI in detection of small hepatocellular carcinoma lesions compared with dynamic contrast-enhanced MRI alone using receiver operating characteristic curve analysis.

Authors:  Peng-Ju Xu; Fu-Hua Yan; Jian-Hua Wang; Jiang Lin; Yuan Ji
Journal:  J Magn Reson Imaging       Date:  2009-02       Impact factor: 4.813

10.  Management of hepatocellular carcinoma: an update.

Authors:  Jordi Bruix; Morris Sherman
Journal:  Hepatology       Date:  2011-03       Impact factor: 17.425

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.